Victor Velculescu

Research output

Research output per year 1993 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2017 2018 2019 2020 2021 2022 2023 2024

• 174 Article
• 14 Review article
• 9 Comment/debate
• 5 Letter
• 6 More
  • 3 Short survey
  • 2 Editorial
  • 1 Conference contribution

Research output per year

Research output per year

Search results

• 2024

  Genome-wide repeat landscapes in cancer and cell-free DNA

  Annapragada, A. V., Niknafs, N., White, J. R., Bruhm, D. C., Cherry, C., Medina, J. E., Adleff, V., Hruban, C., Mathios, D., Foda, Z. H., Phallen, J., Scharpf, R. B. & Velculescu, V. E., Mar 13 2024, In: Science translational medicine. 16, 738, eadj9283.

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2023

  Cell-free DNA approaches for cancer early detection and interception

  Medina, J. E., Dracopoli, N. C., Bach, P. B., Lau, A., Scharpf, R. B., Meijer, G. A., Andersen, C. L. & Velculescu, V. E., Sep 11 2023, In: Journal for immunotherapy of cancer. 11, 9, e006013.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Early Detection of Cancer 75%
  • Medical Overuse 24%
  • Methylation 17%
  • Mutation 11%

• Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer

  Leal, A. I. C., Mathios, D., Jakubowski, D., Johansen, J. S., Lau, A., Wu, T., Cristiano, S., Medina, J. E., Phallen, J., Bruhm, D. C., Carey, J., Dracopoli, N. C., Bojesen, S. E., Scharpf, R. B., Velculescu, V. E., Vachani, A. & Bach, P. B., Oct 2023, In: CHEST. 164, 4, p. 1019-1027 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Lung Neoplasms 62%
  • DNA 24%
  • DNA Fragmentation 18%
  • Denmark 9%

• Corrigendum to “HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade”: [Annals of Oncology volume 33 (2022) 728-738, (S0923753422003921), (10.1016/j.annonc.2022.03.013)]

  Shao, X. M., Huang, J., Niknafs, N., Balan, A., Cherry, C., White, J., Velculescu, V. E., Anagnostou, V. & Karchin, R., Jul 2023, In: Annals of Oncology. 34, 7, p. 634 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Publications 100%
  • Emotions 95%
  • Mutation 67%

• Derivation of CD8⁺ T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis

  Topper, M. J., Anagnostou, V., Marrone, K. A., Velculescu, V. E., Jones, P. A., Brahmer, J. R., Baylin, S. B. & Hostetter, G. H., Jul 21 2023, In: iScience. 26, 7, 107095.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Microenvironment 100%
  • Non-Small Cell Lung Carcinoma 86%
  • Immunotherapy 84%
  • T-Lymphocytes 59%
  • Interferons 44%

• Detecting Liver Cancer Using Cell-Free DNA Fragmentomes

  Foda, Z. H., Annapragada, A. V., Boyapati, K., Bruhm, D. C., Vulpescu, N. A., Medina, J. E., Mathios, D., Cristiano, S., Niknafs, N., Luu, H. T., Goggins, M. G., Anders, R. A., Sun, J., Meta, S. H., Thomas, D. L., Kirk, G. D., Adleff, V., Phallen, J., Scharpf, R. B., Kim, A. K., & 1 othersVelculescu, V. E., Mar 1 2023, In: Cancer discovery. 13, 3, p. 616-631 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Liver Neoplasms 79%
  • DNA Fragmentation 63%
  • Hepatocellular Carcinoma 47%
  • Genome 26%

• Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer

  Sivapalan, L., Iams, W. T., Belcaid, Z., Scott, S. C., Niknafs, N., Balan, A., White, J. R., Kopparapu, P., Cann, C., Landon, B. V., Pereira, G., Velculescu, V. E., Hann, C. L., Lovly, C. M. & Anagnostou, V., Jun 13 2023, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 29, 12, p. 2310-2323 14 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Small Cell Lung Carcinoma 88%
  • Circulating Tumor DNA 57%
  • Tumor Burden 47%
  • Aneuploidy 21%

• Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

  Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., Gibbons, D. L., & 22 othersPennell, N. A., Velcheti, V., Digumarthy, S. R., Mino-Kenudson, M., Califano, A., Heymach, J. V., Herbst, R. S., Brahmer, J. R., Schalper, K. A., Velculescu, V., Henick, B. S., Rizvi, N., Jänne, P. A., Awad, M. M., Chow, A., Greenbaum, B. D., Luksza, M., Shaw, A. T., Wolchok, J., Hacohen, N., Getz, G. & Gainor, J. F., May 2023, In: Nature genetics. 55, 5, p. 807-819 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-Small Cell Lung Carcinoma 100%
  • Whole Exome Sequencing 44%
  • RNA Sequence Analysis 41%
  • Neoplasms 36%
  • Immunotherapy 32%

• H2Bub1 loss is an early contributor to clear cell ovarian cancer progression

  Ferrari, A. J., Rawat, P., Rendulich, H. S., Annapragada, A. V., Kinose, Y., Zhang, X., Devins, K., Budina, A., Scharpf, R. B., Mitchell, M. A., Tanyi, J. L., Morgan, M. A., Schwartz, L. E., Soong, T. R., Velculescu, V. E. & Drapkin, R., 2023, In: JCI Insight. 8, 12, e164995.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ovarian Neoplasms 100%
  • Carcinoma 72%
  • Endometriosis 69%
  • Fingers 60%
  • Histones 41%

• Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells

  van 't Erve, I., Medina, J. E., Leal, A., Papp, E., Phallen, J., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., Karandikar, A., Valkenburg, K. C., Sausen, M., Angiuoli, S. V., Scharpf, R. B., Punt, C. J. A., Meijer, G. A., Velculescu, V. E. & Fijneman, R. J. A., Mar 1 2023, In: Clinical Cancer Research. 29, 5, p. 899-909 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Cell-Free Nucleic Acids 87%
  • High-Throughput Nucleotide Sequencing 66%
  • Colorectal Neoplasms 55%
  • Leukocytes 55%

• Persistent mutation burden drives sustained anti-tumor immune responses

  Niknafs, N., Balan, A., Cherry, C., Hummelink, K., Monkhorst, K., Shao, X. M., Belcaid, Z., Marrone, K. A., Murray, J., Smith, K. N., Levy, B., Feliciano, J., Hann, C. L., Lam, V., Pardoll, D. M., Karchin, R., Seiwert, T. Y., Brahmer, J. R., Forde, P. M., Velculescu, V. E., & 1 othersAnagnostou, V., Feb 2023, In: Nature medicine. 29, 2, p. 440-449 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mutation 100%
  • Tumor Burden 64%
  • Immunotherapy 59%
  • Neoplasms 38%
  • Mesothelioma 20%

• Potential utility of risk stratification for multicancer screening with liquid biopsy tests

  Kim, E. S., Scharpf, R. B., Garcia-Closas, M., Visvanathan, K., Velculescu, V. E. & Chatterjee, N., Dec 2023, In: npj Precision Oncology. 7, 1, 39.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Liquid Biopsy 100%
  • Neoplasms 14%
  • Proof of Concept Study 11%
  • Risk Assessment 7%
  • Smoking 6%

• Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer

  Bruhm, D. C., Mathios, D., Foda, Z. H., Annapragada, A. V., Medina, J. E., Adleff, V., Chiao, E. J., Ferreira, L., Cristiano, S., White, J. R., Mazzilli, S. A., Billatos, E., Spira, A., Zaidi, A. H., Mueller, J., Kim, A. K., Anagnostou, V., Phallen, J., Scharpf, R. B. & Velculescu, V. E., Aug 2023, In: Nature genetics. 55, 8, p. 1301-1310 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Genome 53%
  • Mutation 44%
  • Neoplasms 25%
  • Whole Genome Sequencing 18%
• 2022

  Automated next-generation profiling of genomic alterations in human cancers

  Keefer, L. A., White, J. R., Wood, D. E., Gerding, K. M. R., Valkenburg, K. C., Riley, D., Gault, C., Papp, E., Vollmer, C. M., Greer, A., Hernandez, J., McGregor, P. M., Zingone, A., Ryan, B. M., Deak, K., McCall, S. J., Datto, M. B., Prescott, J. L., Thompson, J. F., Cerqueira, G. C., & 8 othersJones, S., Simmons, J. K., McElhinny, A., Dickey, J., Angiuoli, S. V., Diaz, L. A., Velculescu, V. E. & Sausen, M., Dec 2022, In: Nature communications. 13, 1, 2830.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • tumors 100%
  • cancer 97%
  • oncogenes 46%
  • microsatellites 40%
  • sequencing 35%

• Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

  for the AACR Project GENIE Consortium represented by Shawn Sweeney, Dec 2022, In: Scientific reports. 12, 1, 19055.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lung Neoplasms 100%
  • Neoplasm Metastasis 78%
  • Mutation 70%
  • Non-Small Cell Lung Carcinoma 67%
  • Smoking 18%

• HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade

  Shao, X. M., Huang, J., Niknafs, N., Balan, A., Cherry, C., White, J., Velculescu, V. E., Anagnostou, V. & Karchin, R., Jul 2022, In: Annals of Oncology. 33, 7, p. 728-738 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • HLA Antigens 100%
  • Mutation 54%
  • Non-Small Cell Lung Carcinoma 24%
  • Melanoma 23%
  • Computer Neural Networks 9%

• Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer

  Botsis, T., Murray, J., Leal, A., Palsgrove, D., Wang, W., White, J. R., Velculescu, V. E. & Anagnostou, V., 2022, Advances in Informatics, Management and Technology in Healthcare. Mantas, J., Gallos, P., Zoulias, E., Hasman, A., Househ, M. S., Diomidous, M., Liaskos, J. & Charalampidou, M. (eds.). IOS Press BV, p. 350-353 4 p. (Studies in Health Technology and Informatics; vol. 295).

  Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  Open Access

  • Natural Language Processing 100%
  • Tumors 69%
  • Oncology 45%
  • Genes 32%
  • Decision making 24%

• Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

  Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., Niknafs, N., Zhang, J., Smith, K. N., Sivapalan, L., Chaft, J. E., Reuss, J. E., Marrone, K., Murray, J. C., Li, Q. K., Lam, V., & 7 othersLevy, B. P., Hann, C., Velculescu, V. E., Brahmer, J. R., Forde, P. M., Seiwert, T. & Anagnostou, V., Jun 10 2022, In: Journal for immunotherapy of cancer. 10, 6, e004688.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Blood Cells 93%
  • Neutrophils 88%
  • Lymphocytes 78%
  • Circulating Tumor DNA 36%

• Reply to: Limitations of molecular testing in combination with computerized tomographic for lung cancer screening

  Mathios, D., Bach, P. B., Phallen, J. A., Scharpf, R. B. & Velculescu, V. E., Dec 2022, In: Nature communications. 13, 1, 3892.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy

  Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. & Velculescu, V. E., Nov 9 2022, In: Science translational medicine. 14, 670, eabo3958.

  Research output: Contribution to journal › Review article › peer-review

  • Tumor Biomarkers 100%
  • Immunotherapy 90%
  • Circulating Tumor DNA 36%
  • Liquid Biopsy 35%
  • Neoplasms 33%
• 2021

  Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (Nature, (2021), 596, 7870, (126-132), 10.1038/s41586-021-03752-4)

  Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H. C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., Tam, A., Anagnostou, V., Cottrell, T. R., Guo, H., Chan, H. Y., Singh, D., Thapa, S., Dykema, A. G., Burman, P., Choudhury, B., & 35 othersAparicio, L., Cheung, L. S., Lanis, M., Belcaid, Z., El Asmar, M., Illei, P. B., Wang, R., Meyers, J., Schuebel, K., Gupta, A., Skaist, A., Wheelan, S., Naidoo, J., Marrone, K. A., Brock, M., Ha, J., Bush, E. L., Park, B. J., Bott, M., Jones, D. R., Reuss, J. E., Velculescu, V. E., Chaft, J. E., Kinzler, K. W., Zhou, S., Vogelstein, B., Taube, J. M., Hellmann, M. D., Brahmer, J. R., Merghoub, T., Forde, P. M., Yegnasubramanian, S., Ji, H., Pardoll, D. M. & Smith, K. N., Oct 21 2021, In: Nature. 598, 7881, p. E1

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Lung Neoplasms 100%
  • Names 89%
  • Genes 50%
  • Exome 37%
  • Memory 23%

• Detection and characterization of lung cancer using cell-free DNA fragmentomes

  Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., Chiao, J. Y., Leal, A., Noe, M., White, J. R., Arun, A. S., Hruban, C., Annapragada, A. V., Jensen, S. Ø., Ørntoft, M. B. W., Madsen, A. H., & 18 othersCarvalho, B., de Wit, M., Carey, J., Dracopoli, N. C., Maddala, T., Fang, K. C., Hartman, A. R., Forde, P. M., Anagnostou, V., Brahmer, J. R., Fijneman, R. J. A., Nielsen, H. J., Meijer, G. A., Andersen, C. L., Mellemgaard, A., Bojesen, S. E., Scharpf, R. B. & Velculescu, V. E., Dec 1 2021, In: Nature communications. 12, 1, 5060.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • lungs 86%
  • cancer 74%
  • deoxyribonucleic acid 71%
  • Fragmentation 65%

• Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

  Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Davila, R., Dudek, A. Z., Borghaei, H., Lanis, M., Belcaid, Z., Smith, K. N., Balan, A., White, J. R., Cherry, C., Ashok Sivakumar, I. K., Shao, X. M., Chan, H. Y., Singh, D., & 7 othersThapa, S., Illei, P. B., Pardoll, D. M., Karchin, R., Velculescu, V. E., Brahmer, J. R. & Ramalingam, S. S., Nov 2021, In: Nature medicine. 27, 11, p. 1910-1920 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pemetrexed 100%
  • durvalumab 96%
  • Mesothelioma 66%
  • Cisplatin 60%
  • Platinum 58%

• Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S1535610820304165), (10.1016/j.ccell.2020.08.005))

  Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., Tran, P., Kim, Y. J., Puig-Saus, C., Campbell, K., Vega-Crespo, A., Quist, M., Martignier, C., Luke, J. J., Wolchok, J. D., Johnson, D. B., & 16 othersChmielowski, B., Hodi, F. S., Bhatia, S., Sharfman, W., Urba, W. J., Slingluff, C. L., Diab, A., Haanen, J. B. A. G., Algarra, S. M., Pardoll, D. M., Anagnostou, V., Topalian, S. L., Velculescu, V. E., Speiser, D. E., Kalbasi, A. & Ribas, A., Jan 11 2021, In: Cancer cell. 39, 1, p. 122 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Interferons 100%
  • Melanoma 90%
  • Neoplasms 35%
  • Data Analysis 27%
  • Demography 23%

• KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases

  Van't Erve, I., Wesdorp, N. J., Medina, J. E., Ferreira, L., Leal, A., Huiskens, J., Bolhuis, K., Van Waesberghe, J. H. T. M., Swijnenburg, R. J., Van Den Broek, D., Velculescu, V. E., Kazemier, G., Punt, C. J. A., Meijer, G. A. & Fijneman, R. J. A., 2021, In: JCO Precision Oncology. 5, p. 1758-1767 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Neoplasm Metastasis 100%
  • Mutation 90%
  • Liver 83%
  • Tumor Burden 51%
  • Colorectal Neoplasms 42%

• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

  Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H. C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., Tam, A., Anagnostou, V., Cottrell, T. R., Guo, H., Chan, H. Y., Singh, D., Thapa, S., Dykema, A. G., Burman, P., Choudhury, B., & 35 othersAparicio, L., Cheung, L. S., Lanis, M., Belcaid, Z., El Asmar, M., Illei, P. B., Wang, R., Meyers, J., Schuebel, K., Gupta, A., Skaist, A., Wheelan, S., Naidoo, J., Marrone, K. A., Brock, M., Ha, J., Bush, E. L., Park, B. J., Bott, M., Jones, D. R., Reuss, J. E., Velculescu, V. E., Chaft, J. E., Kinzler, K. W., Zhou, S., Vogelstein, B., Taube, J. M., Hellmann, M. D., Brahmer, J. R., Merghoub, T., Forde, P. M., Yegnasubramanian, S., Ji, H., Pardoll, D. M. & Smith, K. N., Aug 5 2021, In: Nature. 596, 7870, p. 126-132 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Lung Neoplasms 62%
  • Mutation 44%
  • T-Lymphocytes 32%
  • T-Cell Antigen Receptor 26%
• 2020

  Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study

  PLCRC-MEDOCC Group, Aug 20 2020, In: BMC cancer. 20, 1, 790.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Adjuvant Chemotherapy 70%
  • Colonic Neoplasms 62%
  • Cohort Studies 47%
  • Recurrence 18%
  1 Scopus citations

• Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

  Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., Ly, K., Wang, Y., Greenberg, R. A., Schwartz, L., Johnson, N., Scharpf, R. B., Mills, G. B., Zhang, R., Velculescu, V. E., Brown, E. J., & 1 othersSimpkins, F., Dec 1 2020, In: Nature communications. 11, 1, 3726.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • inhibitors 87%
  • Platinum 79%
  • platinum 72%
  • cancer 70%
  13 Scopus citations

• Compartmental analysis of T-Cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

  Zhang, J., Ji, Z., Caushi, J. X., El Asmar, M., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., Chaft, J. E., Reuss, J. E., Tam, A. J., Blosser, R. L., Abu-Akeel, M., Sidhom, J. W., Zhao, N., Ha, J. S., Jones, D. R., Marrone, K. A., & 11 othersNaidoo, J., Gabrielson, E., Taube, J. M., Velculescu, V. E., Brahmer, J. R., Housseau, F., Hellmann, M. D., Forde, P. M., Pardoll, D. M., Ji, H. & Smith, K. N., Mar 15 2020, In: Clinical Cancer Research. 26, 6, p. 1327-1337 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-Small Cell Lung Carcinoma 100%
  • T-Lymphocytes 69%
  • T-Cell Antigen Receptor 64%
  • Residual Neoplasm 50%
  • Neoplasms 36%
  22 Scopus citations

• Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

  Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., Tran, P., Kim, Y. J., Puig-Saus, C., Campbell, K., Vega-Crespo, A., Quist, M., Martignier, C., Luke, J. J., Wolchok, J. D., Johnson, D. B., & 16 othersChmielowski, B., Hodi, F. S., Bhatia, S., Sharfman, W., Urba, W. J., Slingluff, C. L., Diab, A., Haanen, J. B. A. G., Algarra, S. M., Pardoll, D. M., Anagnostou, V., Topalian, S. L., Velculescu, V. E., Speiser, D. E., Kalbasi, A. & Ribas, A., Oct 12 2020, In: Cancer cell. 38, 4, p. 500-515.e3

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Interferons 100%
  • Melanoma 90%
  • Transcriptome 50%
  • Interferon Receptors 43%
  • Ipilimumab 38%
  15 Scopus citations

• Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer

  van 't Erve, I., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., Coupé, V. M. H. & Fijneman, R. J. A., Dec 2020, In: Journal of Molecular Diagnostics. 22, 12, p. 1430-1437 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Liquid Biopsy 97%
  • Colorectal Neoplasms 55%
  • Mutation 33%
  • DNA 16%

• Genomic characterization of malignant progression in neoplastic pancreatic cysts

  Noë, M., Niknafs, N., Fischer, C. G., Hackeng, W. M., Beleva Guthrie, V., Hosoda, W., Debeljak, M., Papp, E., Adleff, V., White, J. R., Luchini, C., Pea, A., Scarpa, A., Butturini, G., Zamboni, G., Castelli, P., Hong, S. M., Yachida, S., Hiraoka, N., Gill, A. J., & 18 othersSamra, J. S., Offerhaus, G. J. A., Hoorens, A., Verheij, J., Jansen, C., Adsay, N. V., Jiang, W., Winter, J., Albores-Saavedra, J., Terris, B., Thompson, E. D., Roberts, N. J., Hruban, R. H., Karchin, R., Scharpf, R. B., Brosens, L. A. A., Velculescu, V. E. & Wood, L. D., Dec 1 2020, In: Nature communications. 11, 1, 4085.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • neoplasms 100%
  • cysts 91%
  • Pancreatic Cyst 90%
  • progressions 70%
  • Mutation 52%
  10 Scopus citations

• High-throughput prediction of MHC Class i and II neoantigens with MH cnuggets

  Shao, X. M., Bhattacharya, R., Huang, J., Sivakumar, I. K. A., Tokheim, C., Zheng, L., Hirsch, D., Kaminow, B., Omdahl, A., Bonsack, M., Riemer, A. B., Velculescu, V. E., Anagnostou, V., Pagel, K. A. & Karchin, R., Mar 1 2020, In: Cancer Immunology Research. 8, 3, p. 396-408 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Major Histocompatibility Complex 100%
  • Peptides 62%
  • Missense Mutation 50%
  • Alleles 35%
  • Datasets 25%
  14 Scopus citations

• Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk

  Esai Selvan, M., Zauderer, M. G., Rudin, C. M., Jones, S., Mukherjee, S., Offit, K., Onel, K., Rennert, G., Velculescu, V. E., Lipkin, S. M., Klein, R. J. & Gümüş, Z. H., Dec 2020, In: Journal of Thoracic Oncology. 15, 12, p. 1871-1879 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenocarcinoma of Lung 100%
  • Whole Exome Sequencing 31%
  • Genes 21%
  • Medical Genetics 17%
  • Confidence Intervals 15%
  1 Scopus citations

• Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma

  Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J. W., Stein, J., Tsai, H. L., Wang, H., Belcaid, Z., Murray, J., Balan, A., Ferreira, L., Ross-Macdonald, P., Wind-Rotolo, M., Baras, A. S., Taube, J., Karchin, R., Scharpf, R. B., Grasso, C., & 4 othersRibas, A., Pardoll, D. M., Topalian, S. L. & Velculescu, V. E., Nov 17 2020, In: Cell Reports Medicine. 1, 8, 100139.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mutation 100%
  • Melanoma 98%
  • T-Lymphocytes 73%
  • Neoplasms 38%
  • B-Lymphocyte Subsets 37%
  4 Scopus citations

• Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

  Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J. E., Smith, K. N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., Hann, C. L., & 15 othersEttinger, D. S., Georgiades, C., Verde, F., Illei, P., Li, Q. K., Baras, A. S., Gabrielson, E., Brock, M. V., Karchin, R., Pardoll, D. M., Baylin, S. B., Brahmer, J. R., Scharpf, R. B., Forde, P. M. & Velculescu, V. E., Jan 1 2020, In: Nature Cancer. 1, 1, p. 99-111 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-Small Cell Lung Carcinoma 100%
  • Tumor Burden 45%
  • Mutation 44%
  • Immunotherapy 42%
  • Neoplasms 36%

• Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

  Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., Wang, D., White, J. R., Yang, S., Battafarano, R., Broderick, S., Bush, E., Brock, M., Ha, J., Jones, D., Merghoub, T., & 12 othersTaube, J., Velculescu, V. E., Rosner, G., Illei, P., Pardoll, D. M., Topalian, S., Naidoo, J., Levy, B., Hellmann, M. D., Brahmer, J. R., Chaft, J. E. & Forde, P. M., Sep 13 2020, In: Journal for immunotherapy of cancer. 8, 2, e001282.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ipilimumab 100%
  • Nivolumab 96%
  • Non-Small Cell Lung Carcinoma 63%
  • Neoplasms 16%
  • Mutation 11%
  13 Scopus citations

• White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer

  Leal, A., van Grieken, N. C. T., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C., Broeckaert, M. A. M., Anagnostou, V., Adleff, V., Bruhm, D. C., Canzoniero, J. V., Fiksel, J., Nordsmark, M., Warmerdam, F. A. R. M., Verheul, H. M. W., van Spronsen, D. J., Beerepoot, L. V., Geenen, M. M., Portielje, J. E. A., Jansen, E. P. M., & 11 othersvan Sandick, J., Meershoek-Klein Kranenbarg, E., van Laarhoven, H. W. M., van der Peet, D. L., van de Velde, C. J. H., Verheij, M., Fijneman, R., Scharpf, R. B., Meijer, G. A., Cats, A. & Velculescu, V. E., Dec 1 2020, In: Nature communications. 11, 1, 525.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • leukocytes 100%
  • Cell-Free Nucleic Acids 90%
  • Circulating Tumor DNA 69%
  • cancer 67%
  • deoxyribonucleic acid 65%
  26 Scopus citations
• 2019

  Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

  the IBCD-Faculty, Jun 2019, In: European Journal of Cancer. 114, p. 128-136 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Precision Medicine 100%
  • Neoplasms 29%
  • Delivery of Health Care 28%
  • Tumor Biomarkers 22%
  • Drug Development 21%
  5 Scopus citations

• Circulating tumor DNA as a clinical test in resected pancreatic cancer

  Groot, V. P., Mosier, S., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., Debeljak, M., Kamiyama, H., Narang, A., Laheru, D. A., Zheng, L., Lin, M. T., Gocke, C. D., Fishman, E. K., Hruban, R. H., Goggins, M. G., & 7 othersQuintus Molenaar, I., Cameron, J. L., Weiss, M. J., Velculescu, V. E., He, J., Wolfgang, C. L. & Eshleman, J. R., Aug 15 2019, In: Clinical Cancer Research. 25, 16, p. 4973-4984 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Pancreatic Neoplasms 65%
  • Adenocarcinoma 24%
  • Recurrence 21%
  • Survival 21%
  27 Scopus citations

• Combined MEK and Bcl-2/X_L inhibition is effective in high-grade serous ovarian cancer patient–derived xenograft models and BIM levels are predictive of responsiveness

  Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., Sampath, D., Mills, G. B. & Brugge, J. S., Mar 2019, In: Molecular cancer therapeutics. 18, 3, p. 642-655 14 p.

  Research output: Contribution to journal › Article › peer-review

  • GDC-0973 100%
  • Mitogen-Activated Protein Kinase Kinases 59%
  • Ovarian Neoplasms 50%
  • Heterografts 49%
  • navitoclax 37%
  17 Scopus citations

• Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x)

  Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T., Awan, A. H., Verde, F., Danilova, L., Anagnostou, V., Tam, A. J., Luber, B. S., Bartlett, B. R., Aulakh, L. K., Sidhom, J. W., Zhu, Q., Sears, C. L., & 21 othersCope, L., Sharfman, W. H., Thompson, E. D., Riemer, J., Marrone, K. A., Naidoo, J., Velculescu, V. E., Forde, P. M., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., Durham, J. N., Wang, H., Le, D. T., Justesen, S., Taube, J. M., Diaz, L. A., Brahmer, J. R., Pardoll, D. M., Anders, R. A. & Housseau, F., Mar 6 2019, In: Journal for immunotherapy of cancer. 7, 1, 7.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Consultants 100%
  • Oncogenes 88%
  • T-Lymphocytes 57%
  • Conflict of Interest 44%
  • Organized Financing 41%
  1 Scopus citations

• Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer

  Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Ashok Sivakumar, I. K., Bruhm, D. C., Rosner, S., Phallen, J., Leal, A., Adleff, V., Smith, K. N., Cottrell, T. R., Rhymee, L., Palsgrove, D. N., Hann, C. L., Levy, B., Feliciano, J., & 16 othersGeorgiades, C., Verde, F., Illei, P., Li, Q. K., Gabrielson, E., Brock, M. V., Isbell, J. M., Sauter, J. L., Taube, J., Scharpf, R. B., Karchin, R., Pardoll, D. M., Chaft, J. E., Hellmann, M. D., Brahmer, J. R. & Velculescu, V. E., 2019, In: Cancer Research. 79, 6, p. 1214-1225 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Non-Small Cell Lung Carcinoma 72%
  • Neoplasms 26%
  • T-Lymphocytes 14%
  • Confidence Intervals 13%
  61 Scopus citations

• Early noninvasive detection of response to targeted therapy in non–small cell lung cancer

  Phallen, J., Leal, A., Woodward, B. D., Forde, P. M., Naidoo, J., Marrone, K. A., Brahmer, J. R., Fiksel, J., Medina, J. E., Cristiano, S., Palsgrove, D. N., Gocke, C. D., Bruhm, D. C., Keshavarzian, P., Adleff, V., Weihe, E., Anagnostou, V., Scharpf, R. B., Velculescu, V. E. & Husain, H., 2019, In: Cancer Research. 79, 6, p. 1204-1213 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Circulating Tumor DNA 100%
  • Non-Small Cell Lung Carcinoma 62%
  • Whole Genome Sequencing 16%
  • Tumor Burden 13%
  • Genetic Therapy 12%
  31 Scopus citations

• Genome-wide cell-free DNA fragmentation in patients with cancer

  Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina, J. E., Hruban, C., White, J. R., Palsgrove, D. N., Niknafs, N., Anagnostou, V., Forde, P., Naidoo, J., Marrone, K., Brahmer, J., Woodward, B. D., Husain, H., van Rooijen, K. L., & 16 othersØrntoft, M. B. W., Madsen, A. H., van de Velde, C. J. H., Verheij, M., Cats, A., Punt, C. J. A., Vink, G. R., van Grieken, N. C. T., Koopman, M., Fijneman, R. J. A., Johansen, J. S., Nielsen, H. J., Meijer, G. A., Andersen, C. L., Scharpf, R. B. & Velculescu, V. E., Jun 20 2019, In: Nature. 570, 7761, p. 385-389 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • DNA Fragmentation 84%
  • Genome 53%
  • Neoplasms 25%
  • Bile Duct Neoplasms 22%
  171 Scopus citations

• Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types

  Mathios, D., Hwang, T., Xia, Y., Phallen, J., Rui, Y., See, A. P., Maxwell, R., Belcaid, Z., Casaos, J., Burger, P. C., McDonald, K. L., Gallia, G. L., Cope, L., Kai, M., Brem, H., Pardoll, D. M., Ha, P., Green, J. J., Velculescu, V. E., Bettegowda, C., & 2 othersPark, C. K. & Lim, M., Dec 15 2019, In: International Journal of Cancer. 145, 12, p. 3425-3435 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • DNA Methylation 100%
  • Glioblastoma 99%
  • Genome 68%
  • Genes 40%
  • Neoplasms 32%
  3 Scopus citations

• Noninvasive detection of microsatellite instabilit and high tumor mutation burden in cancer patients treated with PD-1 blockade

  Georgiadis, A., Durham, J. N., Keefer, L. A., Bartlett, B. R., Zielonka, M., Murphy, D., White, J. R., Lu, S., Verner, E. L., Ruan, F., Riley, D., Anders, R. A., Gedvilaite, E., Angiuoli, S., Jones, S., Velculescu, V. E., Le, D. T., Diaz, L. A. & Sausen, M., Dec 1 2019, In: Clinical Cancer Research. 25, 23, p. 7024-7034 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Microsatellite Instability 100%
  • Microsatellite Repeats 85%
  • Tumor Burden 77%
  • Cell-Free Nucleic Acids 51%
  • Mutation 45%
  31 Scopus citations

• Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

  Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T., Awan, A. H., Verde, F., Danilova, L., Anagnostou, V., Tam, A. J., Luber, B. S., Bartlett, B. R., Aulakh, L. K., Sidhom, J. W., Zhu, Q., Sears, C. L., & 21 othersCope, L., Sharfman, W. H., Thompson, E. D., Riemer, J., Marrone, K. A., Naidoo, J., Velculescu, V. E., Forde, P. M., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., Durham, J. N., Wang, H., Le, D. T., Justesen, S., Taube, J. M., Diaz, L. A., Brahmer, J. R., Pardoll, D. M., Anders, R. A. & Housseau, F., Feb 11 2019, In: Journal for immunotherapy of cancer. 7, 1, 40.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Oncogenes 100%
  • T-Lymphocytes 65%
  • Turcot syndrome 62%
  • Biomarkers 54%
  • DNA Mismatch Repair 50%
  17 Scopus citations

• Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors

  Serrano, C., Leal, A., Kuang, Y., Morgan, J. A., Barysauskas, C. M., Phallen, J., Triplett, O., Mariño-Enríquez, A., Wagner, A. J., Demetri, G. D., Velculescu, V. E., Paweletz, C. P., Fletcher, J. A. & George, S., Dec 15 2019, In: Clinical Cancer Research. 25, 24, p. 7287-7293 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Sunitinib 81%
  • Gastrointestinal Stromal Tumors 76%
  • Protein-Tyrosine Kinases 58%
  • Circulating Tumor DNA 52%
  • Imatinib Mesylate 20%
  12 Scopus citations
• 2018

  A machine learning approach for somatic mutation discovery

  Wood, D. E., White, J. R., Georgiadis, A., Van Emburgh, B., Parpart-Li, S., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., McCord, C., LoVerso, P., Riley, D., Diaz, L. A., Jones, S., Sausen, M., Velculescu, V. E. & Angiuoli, S. V., Sep 5 2018, In: Science translational medicine. 10, 457, aar7939.

  Research output: Contribution to journal › Article › peer-review

  • Machine Learning 100%
  • Mutation 49%
  • Neoplasms 28%
  • Atlases 27%
  • Genome 17%
  25 Scopus citations